295 related articles for article (PubMed ID: 28214655)
1. Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial.
Wiemer EAC; Wozniak A; Burger H; Smid M; Floris G; Nzokirantevye A; Sciot R; Sleijfer S; Schöffski P
Eur J Cancer; 2017 Apr; 75():33-40. PubMed ID: 28214655
[TBL] [Abstract][Full Text] [Related]
2. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
Schöffski P; Ray-Coquard IL; Cioffi A; Bui NB; Bauer S; Hartmann JT; Krarup-Hansen A; Grünwald V; Sciot R; Dumez H; Blay JY; Le Cesne A; Wanders J; Hayward C; Marreaud S; Ouali M; Hohenberger P;
Lancet Oncol; 2011 Oct; 12(11):1045-52. PubMed ID: 21937277
[TBL] [Abstract][Full Text] [Related]
3. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
Schöffski P; Chawla S; Maki RG; Italiano A; Gelderblom H; Choy E; Grignani G; Camargo V; Bauer S; Rha SY; Blay JY; Hohenberger P; D'Adamo D; Guo M; Chmielowski B; Le Cesne A; Demetri GD; Patel SR
Lancet; 2016 Apr; 387(10028):1629-37. PubMed ID: 26874885
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma.
Kawai A; Araki N; Naito Y; Ozaki T; Sugiura H; Yazawa Y; Morioka H; Matsumine A; Saito K; Asami S; Isu K
Jpn J Clin Oncol; 2017 Feb; 47(2):137-144. PubMed ID: 28173193
[TBL] [Abstract][Full Text] [Related]
5. The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study.
Nakamura T; Tsukushi S; Asanuma K; Katagiri H; Ikuta K; Nagano A; Kozawa E; Yamada S; Shido Y; Yamada K; Kawanami K; Ishimura D; Sudo A; Nishida Y
Clin Exp Metastasis; 2019 Aug; 36(4):343-350. PubMed ID: 31209624
[TBL] [Abstract][Full Text] [Related]
6. Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes.
Kobayashi E; Naito Y; Asano N; Maejima A; Endo M; Takahashi S; Megumi Y; Kawai A
Jpn J Clin Oncol; 2019 Oct; 49(10):938-946. PubMed ID: 31365116
[TBL] [Abstract][Full Text] [Related]
7. Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma.
Seetharam M; Kolla KR; Chawla SP
Future Oncol; 2018 Jul; 14(16):1531-1545. PubMed ID: 29411654
[TBL] [Abstract][Full Text] [Related]
8. Eribulin in advanced liposarcoma and leiomyosarcoma.
Setola E; Noujaim J; Benson C; Chawla S; Palmerini E; Jones RL
Expert Rev Anticancer Ther; 2017 Aug; 17(8):717-723. PubMed ID: 28621163
[TBL] [Abstract][Full Text] [Related]
9. Molecular Biomarkers of Response to Eribulin in Patients with Leiomyosarcoma.
Wozniak A; Boeckx B; Modave E; Weaver A; Lambrechts D; Littlefield BA; Schöffski P
Clin Cancer Res; 2021 Jun; 27(11):3106-3115. PubMed ID: 33795257
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.
Emambux S; Italiano A
Expert Opin Pharmacother; 2017 Jun; 18(8):819-824. PubMed ID: 28468516
[TBL] [Abstract][Full Text] [Related]
11. Eribulin in soft-tissue sarcoma.
Young RJ; Woll PJ
Lancet; 2016 Apr; 387(10028):1594-6. PubMed ID: 26874886
[No Abstract] [Full Text] [Related]
12. Sarcoma: Eribulin--a welcomed advance.
Romero D
Nat Rev Clin Oncol; 2016 Apr; 13(4):204. PubMed ID: 26925959
[No Abstract] [Full Text] [Related]
13. Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma.
Sato Y; Nakano K; Fukuda N; Wang X; Urasaki T; Ohmoto A; Yunokawa M; Ono M; Tomomatsu J; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Takahashi S
Anticancer Res; 2021 Jan; 41(1):527-532. PubMed ID: 33419852
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas.
López-Álvarez M; González-Aguilera C; Moura DS; Sánchez-Bustos P; Mondaza-Hernández JL; Martín-Ruiz M; Renshaw M; Ramos R; Castilla C; Blanco-Alcaina E; Hindi N; Martín-Broto J
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614121
[TBL] [Abstract][Full Text] [Related]
15. A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin.
Inagaki C; Shimoi T; Okuma H; Kitano A; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Yoshida A; Fujiwara Y; Tamura K
Anticancer Drugs; 2018 Jan; 29(1):97-101. PubMed ID: 29176397
[TBL] [Abstract][Full Text] [Related]
16. Eribulin Shows Promise in Advanced Sarcoma.
Cancer Discov; 2015 Jul; 5(7):OF4. PubMed ID: 26045011
[No Abstract] [Full Text] [Related]
17. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
18. Complete Response to Eribulin in a Patient with Unresectable Liposarcoma: A Case Report and Implications of New Biomarkers.
Nakamura H; Takada K; Emori M; Hayasaka N; Sugita S
Intern Med; 2022 Dec; 61(23):3617-3621. PubMed ID: 35527027
[TBL] [Abstract][Full Text] [Related]
19. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.
Demetri GD; Schöffski P; Grignani G; Blay JY; Maki RG; Van Tine BA; Alcindor T; Jones RL; D'Adamo DR; Guo M; Chawla S
J Clin Oncol; 2017 Oct; 35(30):3433-3439. PubMed ID: 28854066
[TBL] [Abstract][Full Text] [Related]
20. Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma.
Kawano S; Asano M; Adachi Y; Matsui J
Anticancer Res; 2016 Apr; 36(4):1553-61. PubMed ID: 27069131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
